Chemotherapy, as one of the main options for cancer treatment, has limited selectivity for cancer cells, a narrow therapeutic window, and potential high toxicity, which restricts its clinical application. Antibody-drug conjugates (ADCs), as emerging anticancer therapeutics, can deliver highly cytotoxic molecules directly to cancer cells to exert their lethal effects. ADCs are formed by the … Read more
From “Magic Bullets” to the Birth of ADC Drugs As early as 1913, Paul Ehrlich first proposed the concept of “magic bullets” and drug targeting. However, it wasn’t until the rapid development of antibody technology in the 1970s that the first antibody-drug conjugate (ADC) — Gemtuzumab ozogamicin (GO), targeting CD33, was approved by the FDA … Read more
▉ Introduction Antibody-drug conjugates (ADCs) are composed of monoclonal antibodies that specifically target antigens linked to small molecule cytotoxic drugs via linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor-targeting capability of antibody drugs. ADCs consist of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, … Read more
–01– Introduction For decades, advancements in antibody-drug conjugates (ADC) and bioconjugates have revolutionized targeted therapies for various diseases. Unlike traditional chemotherapy, ADCs selectively target tumor cells while sparing normal cells, making them highly suitable for cancer treatment. Currently, there are 17 types of ADCs approved by regulatory agencies in different countries worldwide. Over 200 more … Read more
Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative approach in cancer treatment, due to their potential for targeted therapy, fewer side effects, broader application, and higher therapeutic index compared to traditional chemotherapy.While ADCs initially focused on hematological malignancies, there has been a clear shift towards solid tumor treatment, with approximately 90% of ADC trials … Read more
Synergistic Breakthroughs in ADC and Novel Antibody Drug Fields: From Industrial Predicaments to Value Reconstruction at Academic Summits When Qide Pharmaceutical’s FGFR3 ADC drug GQ1011 completed global licensing with a total transaction amount exceeding $13 billion, the biopharmaceutical industry witnessed once again the immense potential of antibody-drug conjugates (ADCs). Meanwhile, the $8.4 billion collaboration between … Read more
–01– Introduction Antibody-drug conjugates (ADC) are known as “magic bullets” that precisely target tumor cells through antibodies, delivering cytotoxic drugs while combining the precision of targeted therapy with the potent killing power of chemotherapy. Over the past decade, ADCs have gradually matured in the treatment of solid tumors and hematological malignancies, becoming a revolutionary field … Read more
–01– Introduction Antibody-drug conjugates (ADCs) are known as “magic bullets”, precisely targeting tumor cells through antibodies to deliver cytotoxic drugs, combining the precision of targeted therapy with the potent lethality of chemotherapy. Over the past decade, ADCs have gradually matured in the treatment of solid tumors and hematological malignancies, becoming a revolutionary field in anti-tumor … Read more
Click the blue text above to follow us Editor’s Note: With their unique mechanisms of action and powerful efficacy, Antibody-Drug Conjugates (ADCs) have become indispensable treatment methods for various solid tumors and hematological cancers, such as breast cancer. The core component that determines the efficacy of ADCs is undoubtedly the payload. Different payloads exhibit significant … Read more
Author Introduction Li Yuejun, Director of the Clinical Trial Center and Research Director of the Oncology Medical Center at Hunan Provincial Traditional Chinese Medicine Hospital. Medical Doctor, Chief Physician, Master’s Supervisor, and High-level Health Talent in Hunan Province. Engaged in clinical oncology, research, and teaching for over 10 years. Specializes in multidisciplinary comprehensive treatment of … Read more